<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">30061271</PMID>        <DateCompleted>            <Year>2018</Year>            <Month>08</Month>            <Day>08</Day>        </DateCompleted>        <DateRevised>            <Year>2018</Year>            <Month>08</Month>            <Day>08</Day>        </DateRevised>        <Article PubModel="Print">            <Journal>                <ISSN IssnType="Electronic">1791-7530</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>38</Volume>                    <Issue>8</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Aug</Month>                    </PubDate>                </JournalIssue>                <Title>Anticancer research</Title>                <ISOAbbreviation>Anticancer Res.</ISOAbbreviation>            </Journal>            <ArticleTitle>Relationship Between FDG Uptake and Neutrophil/Lymphocyte Ratio in Patients with Invasive Ductal Breast Cancer.</ArticleTitle>            <Pagination>                <MedlinePgn>4927-4931</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.21873/anticanres.12809</ELocationID>            <Abstract>                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND"><sup>18</sup>F-Fluorodeoxyglucose-positron-emission tomography (FDG-PET) is used to evaluate the glucose metabolic rates of tumors. Several studies have reported that high FDG uptake is predictive of poor prognosis and aggressive features in patients with breast cancer. FDG uptake is influenced by many factors, including inflammation. In this study, the relationship between FDG uptake and neutrophil/lymphocyte ratio (NLR), which is an indicator of systemic inflammation, was investigated.</AbstractText>                <AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">A retrospective investigation of the cases of 143 consecutive patients with invasive ductal carcinoma who had undergone surgery and FDG-PET preoperatively. PET was evaluated using standardized uptake value max (SUV<sub>max</sub>). The median SUV<sub>max</sub> was 2.5 (range=0-10.5). The cases were divided into two groups based on the value of SUV<sub>max</sub>: low (&lt;2.5) and high (≥2.5). The relationships between SUV<sub>max</sub> and clinicopathological features, including NLR, were investigated.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Among the 143 patients, 73 (51.0%) had high SUV<sub>max</sub> in the primary tumor. The analysis revealed that large tumor size (p&lt;0.001), high nuclear grade (p&lt;0.001), the presence of lymphovascular invasion (p&lt;0.001), high C-reactive protein (p=0.046) and high NLR (p&lt;0.001) were significantly associated with high SUV<sub>max</sub> in the primary tumor. SUV<sub>max</sub> and NLR were significantly positively correlated (r=0.323, p&lt;0.001). Among the 70 cases with low SUV<sub>max</sub>, there was no recurrent disease, while out of the 73 cases with high SUV<sub>max</sub> had disease recurrence. It is interesting to note that the group with high SUV<sub>max</sub> and low NLR had no recurrent disease.</AbstractText>                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The present study demonstrated that the finding of high preoperative FDG uptake in breast cancer may be reflective of poor prognosis and that a high NLR may be predictive of aggressive features among patients with breast cancer. On the other hand, among patients with breast cancer with high SUV<sub>max</sub> in the primary tumor, it will be useful to identify those with a low NLR in order to improve prognostic accuracy.</AbstractText>                <CopyrightInformation>Copyright© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Fujii</LastName>                    <ForeName>Takaaki</ForeName>                    <Initials>T</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Breast and Endocrine Surgery, Department of General Surgical Science, Graduate School of Medicine, Gunma University, Gunma, Japan ftakaaki@gunma-u.ac.jp.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Yanai</LastName>                    <ForeName>Keiko</ForeName>                    <Initials>K</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Breast and Endocrine Surgery, Department of General Surgical Science, Graduate School of Medicine, Gunma University, Gunma, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Tokuda</LastName>                    <ForeName>Shoko</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Breast and Endocrine Surgery, Department of General Surgical Science, Graduate School of Medicine, Gunma University, Gunma, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Nakazawa</LastName>                    <ForeName>Yuko</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Breast and Endocrine Surgery, Department of General Surgical Science, Graduate School of Medicine, Gunma University, Gunma, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Kurozumi</LastName>                    <ForeName>Sasagu</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Breast and Endocrine Surgery, Department of General Surgical Science, Graduate School of Medicine, Gunma University, Gunma, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Obayashi</LastName>                    <ForeName>Sayaka</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Breast and Endocrine Surgery, Department of General Surgical Science, Graduate School of Medicine, Gunma University, Gunma, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Yajima</LastName>                    <ForeName>Reina</ForeName>                    <Initials>R</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Breast and Endocrine Surgery, Department of General Surgical Science, Graduate School of Medicine, Gunma University, Gunma, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Hirakata</LastName>                    <ForeName>Tomoko</ForeName>                    <Initials>T</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Breast and Endocrine Surgery, Department of General Surgical Science, Graduate School of Medicine, Gunma University, Gunma, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Shirabe</LastName>                    <ForeName>Ken</ForeName>                    <Initials>K</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Breast and Endocrine Surgery, Department of General Surgical Science, Graduate School of Medicine, Gunma University, Gunma, Japan.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>        </Article>        <MedlineJournalInfo>            <Country>Greece</Country>            <MedlineTA>Anticancer Res</MedlineTA>            <NlmUniqueID>8102988</NlmUniqueID>            <ISSNLinking>0250-7005</ISSNLinking>        </MedlineJournalInfo>        <ChemicalList>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D019275">Radiopharmaceuticals</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0Z5B2CJX4D</RegistryNumber>                <NameOfSubstance UI="D019788">Fluorodeoxyglucose F18</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>9007-41-4</RegistryNumber>                <NameOfSubstance UI="D002097">C-Reactive Protein</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>IY9XDZ35W2</RegistryNumber>                <NameOfSubstance UI="D005947">Glucose</NameOfSubstance>            </Chemical>        </ChemicalList>        <CitationSubset>IM</CitationSubset>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D002097" MajorTopicYN="N">C-Reactive Protein</DescriptorName>                <QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D018270" MajorTopicYN="N">Carcinoma, Ductal, Breast</DescriptorName>                <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D019788" MajorTopicYN="N">Fluorodeoxyglucose F18</DescriptorName>                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005947" MajorTopicYN="N">Glucose</DescriptorName>                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008207" MajorTopicYN="N">Lymphatic Metastasis</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D018655" MajorTopicYN="N">Lymphocyte Count</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008214" MajorTopicYN="N">Lymphocytes</DescriptorName>                <QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D060787" MajorTopicYN="N">Neoplasm Grading</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D009504" MajorTopicYN="N">Neutrophils</DescriptorName>                <QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000072078" MajorTopicYN="N">Positron Emission Tomography Computed Tomography</DescriptorName>                <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D019275" MajorTopicYN="N">Radiopharmaceuticals</DescriptorName>                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>            </MeshHeading>        </MeshHeadingList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">FDG uptake</Keyword>            <Keyword MajorTopicYN="N">FDG-PET</Keyword>            <Keyword MajorTopicYN="N">breast cancer</Keyword>            <Keyword MajorTopicYN="N">inflammation</Keyword>            <Keyword MajorTopicYN="N">neutrophil/lymphocyte ratio</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>06</Month>                <Day>07</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>06</Month>                <Day>18</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>07</Month>                <Day>03</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>8</Month>                <Day>1</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>8</Month>                <Day>1</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>8</Month>                <Day>9</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30061271</ArticleId>            <ArticleId IdType="pii">38/8/4927</ArticleId>            <ArticleId IdType="doi">10.21873/anticanres.12809</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>